Cefamandole nafate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cefamandole nafate
Accession Number
DB14725
Description
Not Available
Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 490.51
Monoisotopic: 490.072924672
Chemical Formula
C19H18N6O6S2
Synonyms
  • O-formylcefamandole

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefamandole nafate is combined with Acenocoumarol.
Acetylsalicylic acidThe therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Cefamandole nafate.
AlteplaseThe therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole nafate.
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Cefamandole nafate.
AnistreplaseThe therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefamandole nafate.
Antithrombin AlfaThe therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefamandole nafate.
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Cefamandole nafate.
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Cefamandole nafate.
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Cefamandole nafate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Cefamandole nafate sodium8HDO7941DO42540-40-9ICZOIXFFVKYXOM-YCLOEFEOSA-M
Active Moieties
NameKindUNIICASInChI Key
Cefamandoleprodrug5CKP8C2LLI34444-01-4OLVCFLKTBJRLHI-AXAPSJFSSA-N
International/Other Brands
Kefadol (Lilly) / Kefandol (Lilly) / Mandokef (Lilly) / Mandol (Lilly)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Mandol Inj 1gm/ampPowder, for solutionIntramuscular; IntravenousEli Lilly & Co. Ltd.1978-12-312000-10-02Canada flag
Mandol Inj 2gm/ampPowder, for solutionIntravenousEli Lilly & Co. Ltd.1978-12-312000-08-03Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
57268-80-1
InChI Key
RRJHESVQVSRQEX-SUYBPPKGSA-N
InChI
InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1
IUPAC Name
(6R,7R)-7-[(2R)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][[email protected]]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[[email protected]]2NC(=O)[[email protected]](OC=O)C1=CC=CC=C1)C(O)=O

References

General References
Not Available
ChemSpider
4447585
RxNav
20473
ChEBI
53654
ChEMBL
CHEMBL1201218
ZINC
ZINC000003830397
Wikipedia
Cefamandole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionIntramuscular; Intravenous
Powder, for solutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.227 mg/mLALOGPS
logP0.61ALOGPS
logP0.42ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.1ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area156.61 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity131.31 m3·mol-1ChemAxon
Polarizability45.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on December 14, 2018 10:21 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates